Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial.

Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Günther R, Zeuzem S, Gösseringer R, Ehrlich A, Neumann K, Wachtlin D, Sprinzl MF, Zimmermann T, Böcher WO, Galle PR.

Dig Liver Dis. 2013 Apr;45(4):323-9. doi: 10.1016/j.dld.2012.11.006. Epub 2012 Dec 13.

PMID:
23245590
2.

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA.

Gut. 2005 Jun;54(6):858-66.

3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
5.

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group.

Antivir Ther. 2005;10(2):309-17.

PMID:
15865225
6.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
7.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
8.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Hepatology. 2008 Jun;47(6):1884-93. doi: 10.1002/hep.22319.

PMID:
18508296
9.

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

Wartelle-Bladou C, Arpurt JP, Renou C, Pariente A, Pillon D, Nalet B, Picon M, Glibert A, Chousterman M, Grasset D, Morin T, Bernard P, Fischer D, Ramdani M, Lagier E, Rotily M; Viral Hepatitis Group of the ANGH.

Gastroenterol Clin Biol. 2006 Apr;30(4):525-32.

10.
11.

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.

Fujino T, Nakamuta M, Aoyagi Y, Kohjima M, Satoh T, Fukuda M, Ishibashi H, Yatsuhashi H, Enjoji M.

Med Sci Monit. 2011 Dec;17(12):CR687-91.

12.

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.

Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group.

Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130.

PMID:
19676125
13.

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.

Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.

Eur J Gastroenterol Hepatol. 2013 May;25(5):601-5. doi: 10.1097/MEG.0b013e32835cc899.

PMID:
23263720
14.

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.

Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F.

Ann Hepatol. 2012 Jan-Feb;11(1):52-61.

15.

Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group.

Aliment Pharmacol Ther. 2012 Aug;36(4):370-8. doi: 10.1111/j.1365-2036.2012.05188.x. Epub 2012 Jun 19.

16.

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.

Urquijo JJ, Diago M, Boadas J, Planas R, Solá R, Del Olmo JA, Crespo J, Erdozaín JC, Antón MD, Arocena C, Suarez D, Giné J, Barrera JM, Gracia-Samaniego J, Perez R, Dalmau B, Montoro M.

Ann Hepatol. 2013 Jan-Feb;12(1):30-5.

17.

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.

Witthöft T, Möller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M, Gelbmann CM, Hüppe D, Niederau C, Alshuth U.

J Viral Hepat. 2007 Nov;14(11):788-96.

18.

S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse.

Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH.

PLoS One. 2010 Nov 8;5(11):e15492. doi: 10.1371/journal.pone.0015492. Erratum in: PLoS One. 2010;5(11). doi: 10.1371/annotation/14d47e6a-400a-429e-a487-6dd375e04632.

20.

A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.

Izumi N, Asahina Y, Kurosaki M, Uchihara M, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S.

Intervirology. 2004;47(2):102-7.

PMID:
15192274
Items per page

Supplemental Content

Write to the Help Desk